期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Bcl-6蛋白表达与非霍奇金淋巴瘤的临床疗效及预后的相关性研究 被引量：2

Expression of Bcl-6 in Non-Hodgkin's lymphoma and its signifiance in clinical curative effect and progonosis
下载PDF
导出
摘要 目的:检测Bc l-6蛋白在非霍奇金淋巴瘤中表达,并研究其与临床疗效及预后的相关性。方法:随机收集128例非霍奇金淋巴瘤病例,并检测Bc l-6蛋白在每例患者非霍奇金淋巴瘤组织中的表达情况,与其临床病理特点相比较,分析其相关性;同时分析Bc l-6蛋白与非霍奇金淋巴瘤预后的相关性。结果:Bc l-6蛋白表达对总生存期(OS),无瘤生存期(DFS)无显著影响;在不同IPI评分组中,Bc l-6蛋白表达差异仅在中高危组的DFS及高危组OS、DFS中有显著性。且Bc l-6蛋白表达与完全缓解(CR)与否无关。结论:Bc l-6蛋白表达是中高危非霍奇金淋巴瘤的预后预测指标,Bc l-6蛋白的阳性表达是预后不良的标志。 Objective：To study the expression of Bcl-6 in non-hodgkin＇s lymphoma and its signifiance in clinical curative effect and progonosis.Methods：128 cases with Non-Hodgkin＇s lymphoma were summarized by their clinical pathology features,meanwhile detecting the expression of Bcl-6 in every case by immunity histochemistry technique,analyzing its correlation with the clinical pathology and progonosis.Results：There was significant relationship between expression of Bcl-6 in non-hodgkin＇s lymphoma and its signifiance in clinical curative effect and progonosis.Conclusions：There was significant relationship between expression of Bcl-6 in non-hodgkin＇s lymphoma and its signifiance in clinical curative effect and progonosis.
作者 吴国武 曾娟紫
机构地区 广东省梅州市人民医院肿瘤内科
出处 《赣南医学院学报》 2011年第4期552-553,共2页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词 乳腺癌 bcl-6蛋白 预后 breast cancer bcl-6 progonosis
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Miura M, Zhu H, RoteUo R, et al. Induction of apoptosis in fibro- blasts by IL-1 converting enzyme, a mammalial homolog of the C elegans cell death gene ceds [ J ]. Cell, 1993, 75: 653.
  • 2Lazebnik YA, Kaufmann SH, Desnoyers D, et al. Cleavage of poly (-ADP- ribose) polymerase by proteinase with properties like ICE [ J ]. Nature, 1994,371:346-347.
  • 3Jaffe ES, Harris NL, Diebold J,et al. World Health Or- ganization classi-fication of neoplastic diseases of the he- matopoitic and lymphoid tissues: a progress report [ J ]. Am J Clin Pathol, 1999,111 (Supp 11) :8-12.
  • 4Offit K, Jhanwar S, Ebrahim SA, et al. t ( 3 ; 22 ) ( q27 ; q11 ) : a novel translocation associated with diffuse non- Hodgkin's lymphoma [ J ]. Blood, 1989,74 (6) : 1876.
  • 5Ladanyi M, Offit K, Parsa NZ, et al. Follicular lymphoma with t(8;14) (q24;q32) : a distinct clinical and molecu- lar subset of t ( 8 ; 14 ) -beating lymphomas [ J ]. Blood, 1992,79(8) :2124-2130.
  • 6Chen W, Lida S, Louie DC, et al. Heterologous promotors fused to Bcl-6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B cell differentiation [ J ]. Blood, 1998,91 ( 2 ) : 6034507.
  • 7Chang CC, Kampalath B, Schultz C, et al. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in prima- ry central nervous system diffuse large B-cell lymphoma a- mong immunocompetent individuals [ J ]. Arch Pathol Lab Med,2003,127 (2) : 208 - 12.
  • 8Braaten KM, Betensky RA, de Leval L, et al. BCL-6 ex- pression predicts improved survival in patients with prima- ry central nervous system lymphoma [ J ]. Clin Cancer Res, 2003,9(3) :1063.
  • 9Durnick DK, Law ME, Maurer MJ, et al. Expression of LMO2 is associated with t( 14; 18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma [ J ]. Am J Clin Pathol, 2010,134 ( 2 ) : 278-281.

同被引文献32

  • 1No authors listed.A predictive model for aggressive non-Hodgkin's lymphomas.The International Non-Hodgkin's Lymphoma Prognostic Factors Project[J].N Engl J Med,1993,329 (14):987-994.
  • 2崔丽娟,白晓川.非霍奇金淋巴瘤预后相关因素分析[J].亍夏医科大学学报,2009,31(3)343-345.
  • 3Wei G,Yuping Z,Jun W,et al.CA125 expression in patients with non-Hodgkin's lymphoma[J].Leuk Lymphoma,2006,47 (7):1322-1326.
  • 4Vet JA,Bringuier PP,Schaafsma HE,et al.Comparision of p53 protein over expression with p53 mutation in bladder cancer:clinical and biologic aspects[J].Lab Invest,1995,73(6):837-843.
  • 5Navaramam S,Williams GJ,Rubinger M,et al.Expression of p53 predicts treatment failure in aggressive non-Hodgkins lymphoma[J].Leuk Lymphoma,1998,29 (1/2):139-144.
  • 6Aoyagi K,Kohfuji K,Yano S,et al.The expression of prolife rating cell nuclear antigen,p53,p21,and apoptosis in primary gastriclym phoma[J].Surgery,2002,132(1):20-26.
  • 7Agape P,Copin MC,Cavrois M,et al.Implication of HTLV-I infection,strongyloidiasis,and P53 over expression in the development,response to treatment,and evolution of non-Hodgkin's lymphomas in an endemic area (Mart inique,French West Indies)[J].J Acquir Immune Defic Syndr Hum Retrovirol,1999,20(4):394-402.
  • 8Ling V,Thompsont LH.Reduced permeability in CHO cell as a mechanism of resistance to colchnicines[J].J Cell Physiol,1974,83(1):103-116.
  • 9Paydas S,Ergin M,Erdogan S,et al.Thrombospondin1 (TSP-1) and Survivin(S) expression in non-Hogkin' s lymphomas[J].Leuk Res,2008,32 (2):243-250.
  • 10Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25)breakdown of a single mechanism of self tolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151-1164.

引证文献2

二级引证文献7

赣南医学院学报
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部